Welcome to our dedicated page for Sensus Healthcare news (Ticker: SRTS), a resource for investors and traders seeking the latest updates and insights on Sensus Healthcare stock.
Sensus Healthcare, Inc. (Nasdaq: SRTS) is a leading medical device company dedicated to providing non-invasive and cost-effective treatments for non-melanoma skin cancer and keloids. Utilizing a proprietary low-energy x-ray radiation technology known as Superficial Radiation Therapy (SRT), Sensus Healthcare has made significant advancements in the field over more than a decade of dedicated research and development. The company’s flagship products, the SRT-100™ and SRT-100 Vision™, effectively and safely treat a variety of oncological and non-oncological skin conditions, including basal cell and squamous cell skin cancers, as well as keloids.
Based in Boca Raton, Florida, Sensus Healthcare focuses on creating innovative, minimally-invasive solutions that address critical medical needs. The company has recently announced a multi-faceted collaboration with CureRays, a radiation oncology specialist organization headquartered in Atlanta and Grass Valley, California. This partnership aims to enhance the reach and efficacy of Sensus's SRT technology, further solidifying its position as a leader in the non-invasive treatment market.
Sensus Healthcare generates the majority of its revenue from customers within the United States, offering products and services that meet the highest standards of safety and effectiveness. The company’s proprietary technology has been incorporated into its diverse portfolio, which includes the SRT-100™, SRT-100 Vision™, and a comprehensive Sentinel service program that ensures optimal device performance and customer satisfaction.
Investors and stakeholders are encouraged to stay informed about Sensus Healthcare’s latest developments. Recently, the company announced it would hold a conference call on May 9, 2024, to discuss the financial results for the first quarter of 2024 and provide updates on recent and upcoming milestones. This call will offer an in-depth overview of the company’s financial health and strategic initiatives.
For more detailed information about Sensus Healthcare, its innovative technology, products, and recent news, please visit Sensus Healthcare’s official website.
On May 18, 2022, Sensus Healthcare (Nasdaq: SRTS) announced its participation in the H.C. Wainwright Global Investment Conference, scheduled for May 23-26, 2022. The company will present on May 25 at 9:30 a.m. Eastern time, with the presentation available live and archived on its website. Additionally, Sensus management, including President Michael Sardano and CFO Javier Rampolla, will hold one-on-one meetings with investors during the conference. Sensus specializes in non-invasive treatments for oncological and non-oncological conditions, utilizing proprietary low-energy X-ray technology.
Sensus Healthcare (SRTS) reported first quarter 2022 revenues of $10.3 million, a 237% increase compared to the previous year. Net income surged to $16.1 million, or $0.97 per diluted share, thanks to a $12.8 million gain from asset sales. The company exited the quarter with $32.8 million in cash. Adjusted EBITDA improved to $16.9 million, up from a loss of $0.8 million year-on-year. Sensus affirms expectations for continued growth and profitability in Q2 and the full year.
Sensus Healthcare, Inc. (Nasdaq: SRTS) has announced a conference call scheduled for May 5, 2022, at 4:30 p.m. Eastern time to discuss its financial results for Q1 2022. The call will also include a business update covering recent and upcoming milestones. Investors can access the call via dial-in numbers or through a live webcast on the company's website. Sensus Healthcare specializes in non-invasive treatments for oncological and non-oncological conditions, utilizing low-energy X-ray technology for various medical applications.
Sensus Healthcare (Nasdaq: SRTS) recently announced successful treatments using its SRT-100 system, demonstrating its capability in veterinary oncology. A mata mata turtle at Denver Zoo was treated for squamous cell carcinoma, showing no signs of the lesion three months post-therapy. This follows earlier treatments on various animals at Colorado State University, expanding the application of SRT in veterinary medicine. The ongoing partnership with CSU aims to develop protocols and clinical data, highlighting potential growth in a new market segment.
Sensus Healthcare (Nasdaq: SRTS), a medical device company, is set to present at two investment conferences in March 2022. The 34th Annual ROTH Conference will be held from March 13-15, with a key ‘Fireside Chat’ on March 15 at 9:30 a.m. PT. Investors can access the chat and a pre-recorded presentation on the company's website. Additionally, Sensus will participate in the Maxim 2022 Virtual Growth Conference on March 28-29, joining an Aesthetic Device Industry Panel on March 28 from 1:00 p.m. to 2:30 p.m. ET.
Sensus Healthcare, Inc. (Nasdaq: SRTS) announced a share buyback program authorizing the purchase of up to $3,000,000 of its common stock. CEO Joe Sardano expressed optimism about the company's future and stated that the buyback is a strategy to enhance shareholder value. The program, which has no time limit, allows for purchases through various methods and is subject to management's discretion based on financial assessments and market conditions. Sensus specializes in non-invasive medical device treatments for cancer and other conditions.
Sensus Healthcare (Nasdaq: SRTS) has sold its Sculptura™ assets to Empyrean Medical Systems for $15 million in cash, completing the transaction on February 25, 2022. The sale allows Sensus to concentrate on its core dermatology business as it rebounds, utilizing proceeds to expand its dermatology product line, including new offerings like the TransDermal™ Infusion system and Laser Systems. This move aligns with Sensus's strategy to focus resources post-sale, which positions the company for growth in the dermatological segment.
Sensus Healthcare, Inc. (SRTS) reported a remarkable fourth quarter 2021 with revenues of $13.0 million, surging 156% year-over-year. Net income reached $5.3 million or $0.32 per diluted share, compared to $1.0 million or $0.06 in Q4 2020. The full-year revenue climbed to $27.0 million, a 182% increase from 2020. Positive momentum is expected to continue into 2022, bolstered by new product agreements and improved reimbursement rates. Management anticipates profitability for both the first quarter and full year of 2022.
Sensus Healthcare (Nasdaq: SRTS) announced key executive promotions as part of its strategy for long-term growth. Michael J. Sardano has been promoted to President, while Christopher Machuzak and Jeffrey Starling are now Vice Presidents of Sales for the West and East Coasts, respectively. This decision reflects the company's commitment to develop talent internally and enhance its leadership team. The announcement also included the retirement of Executive Vice President and Co-founder Steve Cohen. These changes aim to leverage leadership strengths and drive sustained sales growth, especially post-COVID-19.
FAQ
What is the current stock price of Sensus Healthcare (SRTS)?
What is the market cap of Sensus Healthcare (SRTS)?
What is Sensus Healthcare, Inc.?
What products does Sensus Healthcare offer?
What is Superficial Radiation Therapy (SRT)?
Where is Sensus Healthcare based?
What recent collaborations has Sensus Healthcare announced?
How does Sensus Healthcare generate its revenue?
What is the Sentinel service program?
When is the next conference call for Sensus Healthcare?
Where can I find more information about Sensus Healthcare?